Section
Recent clinical trials reveal the therapeutic potential of Akkermansia muciniphila strains in alleviating respiratory symptoms, improving muscle strength, and preventing diet-induced obesity in dogs.
Nasal high flow therapy modestly improves tidal volume and dyspnoea during exercise in severe COPD but has minimal effect on respiratory muscle workload or endurance capacity.
The first international paediatric bronchiectasis registry highlights significant regional differences in causes, management, and care quality, underscoring urgent needs for harmonized standards and improved multidisciplinary support.
AI decision support significantly improves primary care clinicians’ accuracy in spirometry diagnosis, especially for COPD, addressing a key gap in respiratory disease management.
COPD in adults under 50 affects 4.5% of this population and is linked to increased risks of early mortality and serious cardiopulmonary events, underscoring the need for early identification and intervention.
A randomized clinical trial demonstrates that an Acceptance and Commitment Therapy-based parenting program reduces health care use, improves asthma control, and alleviates ADHD symptoms in children with both conditions.
Minority children and those from lower socioeconomic backgrounds receive significantly more and broader-spectrum antibiotics for pneumonia during hospitalization than non-Hispanic White counterparts, contrary to outpatient trends.
Explore the differences, uses, and safety of ibuprofen and acetaminophen for managing fever effectively.
Vaccinating new older adult care home residents with PCV20 or PPV23 could prevent substantially more invasive pneumococcal disease cases and deaths per dose than standard age-based vaccination, supporting policy revision.
A phase 4 trial in The Gambia finds that maternal Tdap-IPV vaccination is safe and provides early infant protection, but modestly blunts immune responses to whole-cell pertussis vaccines without compromising overall immunogenicity.
Dupilumab significantly reduced type 2 inflammation biomarkers and exacerbation risk in COPD patients with elevated eosinophils, highlighting the value of biomarker-driven therapy.
Sotatercept significantly reduces the risk of death, lung transplantation, or hospitalization in high-risk pulmonary arterial hypertension patients, marking a major advance in the management of this life-threatening disease.
Navigational bronchoscopy offers noninferior diagnostic accuracy to transthoracic needle biopsy for peripheral pulmonary nodules, with notably fewer pneumothorax complications.
Phase 3 trials demonstrate that nerandomilast, a selective PDE4B inhibitor, significantly slows lung function decline in idiopathic and progressive pulmonary fibrosis over 52 weeks, with manageable safety profiles.
As-needed albuterol–budesonide significantly reduces severe exacerbations in mild asthma compared to albuterol alone, with comparable safety. Two pivotal trials confirm efficacy across lung function and exacerbation outcomes.
A recent multicenter trial demonstrates methotrexate’s noninferiority to prednisone in improving lung function at 24 weeks in pulmonary sarcoidosis, with distinct side-effect profiles informing treatment choices.
A multicenter US study highlights the devastating burden of influenza-associated acute necrotizing encephalopathy in children, with high mortality and disability rates despite aggressive therapy, underscoring the urgent need for prevention
A randomized trial shows that a smartphone-based asthma self-management program improves symptom control in adults, though its effectiveness is attenuated in African American participants.
Persistent cough in children may stem from ear, nose, and throat conditions like allergic rhinitis, upper airway cough syndrome, or chronic tonsillitis.
